The National Comprehensive Cancer Network (NCCN) guidelines recommend EGFR-TKI therapy for patients with EGFR mutations, as it significantly improves progression-free and overall survival in EGFR-mutant non-small cell lung cancer (NSCLC) (5). This evidence concerns the gene EGFR and non-small cell lung carcinoma.